Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

Antimicrob Agents Chemother. 2010 Nov;54(11):4939-41. doi: 10.1128/AAC.00441-10. Epub 2010 Sep 7.

Abstract

Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venovenous hemodiafiltration (CVVHDF) provided no deterioration in renal function after treatment. High dosage of aminoglycosides combined with CVVHDF may represent a valuable therapeutic option for infection due to multiresistant pathogens.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amikacin / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • C-Reactive Protein / metabolism
  • Creatinine / metabolism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / pathogenicity*
  • Sepsis / drug therapy*
  • Sepsis / metabolism
  • Sepsis / microbiology*

Substances

  • Anti-Bacterial Agents
  • Amikacin
  • C-Reactive Protein
  • Creatinine